Loading...
XNAS
IMGN
Market cap1.06bUSD
Feb 09, Last price  
31.23USD
Name

ImmunoGen Inc

Chart & Performance

D1W1MN
XNAS:IMGN chart
P/E
—
P/S
80.20
EPS
—
Div Yield, %
—
Shrs. gr., 5y
20.93%
Rev. gr., 5y
-1.18%
Revenues
109m
0.00%
25,955,73035,718,00032,088,00038,212,00040,249,00027,988,00013,943,00019,305,00016,357,00035,535,00059,896,00085,541,00060,002,00048,628,000115,447,00053,816,00082,271,000132,299,000108,782,000108,782,000
Net income
-223m
L-0.00%
-5,916,741-10,951,000-17,834,000-18,987,000-32,020,000-31,937,000-50,912,000-58,274,000-73,319,000-72,811,000-71,364,000-60,739,000-143,655,000-156,733,000-96,012,000-167,873,000-122,093,000-66,683,000-222,929,000-222,929,000
CFO
-230m
L-0.00%
-5,015,855-2,065,000-14,281,000-15,781,000-20,149,000-13,334,000-40,584,000-7,989,000-34,288,000-60,299,000-53,650,000-55,291,000-124,476,000-142,642,0007,645,000-166,422,000-88,367,000-78,620,000-229,802,000-229,802,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
URL
https://www.immunogen.com/
IPO date
Nov 17, 1989
Employees
277
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑122016‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT